CYP19A1 and breast cancer: In this context, AIs development started in the early 1970s, when researchers recognized that aromatase could represent a therapeutic target in hormone-dependent BC [12], and several molecules with different biological properties were identified, and classified according to their specificity in inhibiting aromatase [13].